SynthesisHealth technology assessment (Winchester, England)2026

Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.

Catalina Lopez Manzano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.